ANN ARBOR, Mich., March 19, 2019 /PRNewswire/ — Strata OncologyTM, a leading precision oncology company, today announced the launch of version 3.0 of StrataNGSTM, its pan-cancer assay for solid tumors. The updated 500-gene assay utilizes DNA and RNA from tumor samples to detect all clinically actionable biomarkers — including microsatellite instability (MSI), tumor mutational burden (TMB), and PD-L1 — recommended by leading guidelines, in a single test. Test results are provided in a streamlined report that facilitates rapid, confident interpretation and identification of potential treatment options and clinical trials.
“Our expanded assay, providing deep cancer insights and leading performance, represents our commitment to bring a best-in-class diagnostic to oncologists and pathologists across the Strata network of health systems,” said Scott Tomlins, M.D., Ph.D., Chief Medical Officer of Strata Oncology. “In addition to providing physicians with all relevant genomic information needed to make an informed treatment decision, the test will help inform new trial design and accelerate drug development.”
Read more here.